Literature DB >> 36167548

Correction: M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID.

Valérie Martel-Laferrière1,2,3, Daniel J Feaster4, Lisa R Metsch5, Bruce R Schackman6, Christine Loignon7, Bohdan Nosyk8, Hansel Tookes4, Czarina N Behrends6, Nelson Arruda9, Oluleye Adigun10, Marie-Eve Goyer11, Michael A Kolber4, Jean-Francois Mary12, Allan E Rodriguez4, Iveth G Yanez5, Yue Pan13, Rania Khemiri14, Lauren Gooden5, Aïssata Sako14, Julie Bruneau15,11,14.   

Abstract

Entities:  

Year:  2022        PMID: 36167548      PMCID: PMC9513950          DOI: 10.1186/s13063-022-06724-9

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.728


× No keyword cloud information.
Correction: Trials 23, 341 (2022) https://doi.org/10.1186/s13063-022-06085-3 Following the publication of the original article [1], we were notified of a typo in Dr Bruce Schackman's last name. Originally published name: Bruce Shackman Correct name: Bruce Schackman The original article has been corrected.
  1 in total

1.  M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID.

Authors:  Valérie Martel-Laferrière; Daniel J Feaster; Lisa R Metsch; Bruce R Shackman; Christine Loignon; Bohdan Nosyk; Hansel Tookes; Czarina N Behrends; Nelson Arruda; Oluleye Adigun; Marie-Eve Goyer; Michael A Kolber; Jean-Francois Mary; Allan E Rodriguez; Iveth G Yanez; Yue Pan; Rania Khemiri; Lauren Gooden; Aïssata Sako; Julie Bruneau
Journal:  Trials       Date:  2022-04-23       Impact factor: 2.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.